No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EVAX Evaxion Biotech
- 4.120
- -0.010-0.24%
Close Apr 25 16:00 ET
- 4.010
- -0.110-2.67%
Post 16:14 ET
21.49MMarket Cap-508P/E (TTM)
4.130High3.850Low7.19KVolume4.110Open4.130Pre Close28.97KTurnover0.20%Turnover RatioLossP/E (Static)5.22MShares18.50052wk High-4.54P/B14.89MFloat Cap2.82452wk Low--Dividend TTM3.61MShs Float250.400Historical High--Div YieldTTM6.78%Amplitude2.824Historical Low4.032Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Evaxion Biotech's Strategic Financial Plans
Express News | Evaxion Announces First Patient Completed Dosing With Personalized Cancer Vaccine EVX-01
Express News | Evaxion Biotech A/S - Favorable Safety Profile Confirmed
Express News | Evaxion Biotech A/S - Trial on Track for One-Year Clinical Efficacy Readout in Q3 2024
Express News | Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine Evx-01
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were weaker Thursday morning, falling 0.91% to 1,353.49 on the S&P Europe Select ADR Index.
Comments
Update
$Evaxion Biotech(EVAX.US$ Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies.
MT Newswires· 1 min ago
MT Newswires· 1 min ago
$Evaxion Biotech(EVAX.US$ Evaxion Biotech beat estimated earnings by 90.0%, that's great news!!
$Evaxion Biotech(EVAX.US$ Great R&D Day presentation this afternoon at Evaxion headquaters. Looks like 24-25 will be great years, and the possibilities with these AI models will most definitely break grounds and push up. 🙌
(EVAX) Price Target Increased by 414.29% to 18.36
Story by George Maybach •
The average one-year price target for Evaxion Biotech A (NasdaqCM:EVAX) has been revised to 18.36 / share. This is an increase of 414.29% from the prior estimate of 3.57 dated January 16, 2024.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 14.14 to a high of 21.00 / share. The average price target represents an increase of 392.23% from the latest reported cl...
The average one-year price target for Evaxion Biotech A (NasdaqCM:EVAX) has been revised to 18.36 / share. This is an increase of 414.29% from the prior estimate of 3.57 dated January 16, 2024.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 14.14 to a high of 21.00 / share. The average price target represents an increase of 392.23% from the latest reported cl...
1
Update
$Evaxion Biotech(EVAX.US$ Press Release: Evaxion Regains Compliance With Nasdaq Minimum Bid Price Requirement
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg